Institutional Investors Weigh In On Enanta Pharmaceuticals News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Institutional investors weigh in on enanta pharmaceuticals. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Institutional Investors Weigh In On Enanta Pharmaceuticals Today - Breaking & Trending Today

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA – Get Free Report) has earned an average rating of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have assigned a buy rating to the company. […] ....

Acadian Asset Management , Enanta Pharmaceuticals Inc , Armistice Capital , Enanta Pharmaceuticals Stock Performance , News Ratings For Enanta Pharmaceuticals Daily , Jpmorgan Chase Co , Analyst Recommendations For Enanta Pharmaceuticals , Enanta Pharmaceuticals , Institutional Investors Weigh In On Enanta Pharmaceuticals , Vanguard Group Inc , Krensavage Asset Management , Get Free Report , Asset Management , Get Free , Enanta Pharmaceuticals Daily ,

Enanta Pharmaceuticals (NASDAQ:ENTA) Upgraded by StockNews.com to "Hold"

StockNews.com upgraded shares of Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) from a sell rating to a hold rating in a research report sent to investors on Friday. Separately, JPMorgan Chase & Co. lowered their price target on Enanta Pharmaceuticals from $12.00 to $11.00 and set an underweight rating on the stock in a report on […] ....

Enanta Pharmaceuticals Inc , Nisa Investment Advisors , Institutional Investors Weigh In On Enanta Pharmaceuticals , News Ratings For Enanta Pharmaceuticals Daily , Tower Research Capital , Enanta Pharmaceuticals , Clearstead Advisors , Royal Bank , Analyst Recommendations For Enanta Pharmaceuticals , Enanta Pharmaceuticals Company Profile , Jpmorgan Chase Co , Us Bancorp , Enanta Pharmaceuticals Stock Performance , Free Report , Get Free Report , Investment Advisors , Research Capital , Enanta Pharmaceuticals Daily ,

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Average Recommendation of "Hold" from Analysts
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Terry Vance , Securities Exchange Commission , Institutional Investors Weigh In On Enanta Pharmaceuticals , Krensavage Asset Management , Acadian Asset Management , Enanta Pharmaceuticals Stock Performance , Insider Activity At Enanta Pharmaceuticals , Enanta Pharmaceuticals Company Profile , News Ratings For Enanta Pharmaceuticals Daily , Enanta Pharmaceuticals Inc , Enanta Pharmaceuticals , Royal Bank , Analyst Recommendations For Enanta Pharmaceuticals , Get Free Report , Exchange Commission , Director Terry Vance , Asset Management , State Street Corp , Street Corp , Get Free , Enanta Pharmaceuticals Daily ,

Enanta Pharmaceuticals (NASDAQ:ENTA) Price Target Lowered to $28.00 at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price objective lowered by HC Wainwright from $30.00 to $28.00 in a report issued on Tuesday, Benzinga reports. The brokerage currently has a buy rating on the biotechnology company’s stock. A number of other analysts have also weighed in on ENTA. JPMorgan Chase & Co. lowered shares […] ....

Jpmorgan Chase Co , Analyst Recommendations For Enanta Pharmaceuticals , Institutional Investors Weigh In On Enanta Pharmaceuticals , Jefferies Financial Group , Sei Investments Co , Krensavage Asset Management , Walleye Capital , Enanta Pharmaceuticals Trading , Enanta Pharmaceuticals , Enanta Pharmaceuticals Inc , Abbott Laboratories , Royal Bank , News Ratings For Enanta Pharmaceuticals Daily , Deutsche Bank , Free Report , Get Free Report , Asset Management , Laurion Capital Management , Enanta Pharmaceuticals Daily , Nasdaq Enta , Lower Price Target , Hc Wainwright ,

Enanta Pharmaceuticals (NASDAQ:ENTA) PT Lowered to $23.00

Enanta Pharmaceuticals (NASDAQ:ENTA – Free Report) had its price target trimmed by JMP Securities from $42.00 to $23.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an outperform rating on the biotechnology company’s stock. Other research analysts have also recently issued reports about the company. Jefferies Financial Group […] ....

News Ratings For Enanta Pharmaceuticals Daily , Enanta Pharmaceuticals Stock Performance , Institutional Investors Weigh In On Enanta Pharmaceuticals , Clearstead Advisors , Enanta Pharmaceuticals Company Profile , Financial Services Group Inc , Enanta Pharmaceuticals , Tower Research Capital , Analyst Recommendations For Enanta Pharmaceuticals , Jefferies Financial Group , Royal Bank , Jpmorgan Chase Co , Abbott Laboratories , Enanta Pharmaceuticals Inc , Free Report , Financial Group , Get Free Report , Research Capital , Services Group , Captrust Financial Advisors , Financial Advisors , Enanta Pharmaceuticals Daily , Nasdaq Enta , Lower Price Target , Jmp Securities ,